

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

A223

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 47/46, 47/28, 47/26, C07G 3/00, C07J 63/00	A1	(11) International Publication Number: WO 96/11711 (43) International Publication Date: 25 April 1996 (25.04.96)
(21) International Application Number: PCT/AU95/00670 (22) International Filing Date: 12 October 1995 (12.10.95) (30) Priority Data: PM 8732 12 October 1994 (12.10.94) AU (71) Applicant (for all designated States except US): ISCOTEC AB [SE/SE]; Birger Jarlsgaten 16, S-103 91 Stockholm (SE). (72) Inventors; and (75) Inventors/Applicants (for US only): COX, John, Cooper [AU/AU]; 365 Bacchus Marsh Road, Bullengarook, VIC 3437 (AU). COULTER, Alan, Robert [AU/AU]; 14 Somerset Road, Glen Iris, VIC 3146 (AU). MOREIN, Bror [SE/SE]; Olionstigen 3, Vreta, S-755 90 Uppsala (SE). LOVGREN-BENGTSSON, Karin [SE/SE]; Lindsbergsgatan 8C, S-752 40 Uppsala (SE). SUNDQUIST, Bo [SE/SE]; Bellmansgatan 30, S-754 28 Uppsala (SE). (74) Agents: SLATTERY, John, Michael et al.; Davies Collison Cave, 1 Little Collins Street, Melbourne, VIC 3000 (AU).		(81) Designated States: AU, CA, FI, JP, KR, NO, NZ, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: SAPONIN PREPARATIONS AND USE THEREOF IN ISCOMS (57) Abstract A preparation of saponins of <i>Quillaja saponaria</i> , comprises fractions of Quil A having good adjuvant activity, low haemolytic activity and good ability to form immunostimulatory complexes (iscoms).		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

SAPONIN PREPARATIONS AND USE THEREOF IN ISCOMS

FIELD OF THE INVENTION

This invention relates to saponin preparations, particularly to saponin
5 preparations based on defined compositions of purified saponin fractions derived
from the bark of *Quillaja saponaria* Molina. The invention also extends to
immunostimulating complex (iscom) matrices prepared using these saponin
preparations, as well as to immunogenic iscoms in which immunogens are
incorporated into or associated with an iscom matrix. Such immunogens will
10 usually be proteins or peptides derived from bacteria, viruses or other
microorganisms, but they may, in addition, be any other protein, peptide or other
chemical entity which can induce an immune response.

The saponin preparations of this invention, and iscom matrices prepared
15 using them, have particular activity as adjuvants, that is as products which result
in a specific increase in the immunogenicity of a vaccine component.

BACKGROUND OF THE INVENTION

The adjuvant properties of saponin have been long known, as has its
20 ability to increase antibody titres to immunogens. As used herein, the term
"saponin" refers to a group of surface-active glycosides of plant origin composed
of a hydrophilic region (usually several sugar chains) in association with a
hydrophobic region of either steroid or triterpenoid structure. Although saponin
is available from a number of diverse sources, saponins with useful adjuvant
25 activity have been derived from the South American tree *Quillaja saponaria*
Molina. Saponin from this source was used to isolate a "homogeneous" fraction
denoted "Quil A" (Dalsgaard, 1974).

Acute toxicity is a major concern for both the veterinary and human use of
30 Quil A in vaccine preparations. One way to avoid the acute toxicity of Quil A is
the use of iscoms, an abbreviation for Immuno Stimulating COMplexes. This is
primarily because Quil A is less toxic when incorporated into iscoms, because its

- 2 -

association with cholesterol in the iscom reduces its affinity for cholesterol in cell membranes and hence its cell lytic effects. In addition, a lesser amount of Quil A is required to generate a similar level of adjuvant effect. Iscoms are small, cage-like structures generally 30 to 40 nm in diameter which retain this structure on freeze drying. The final formulation of a typical immunogenic iscom with an optimal amount of immunogenic protein is a weight ratio of Quil A, cholesterol, phosphatidyl choline, and protein (1:1:1:5). Such a typical iscom is estimated to contain 5 to 10% by weight Quil A, 1 to 5% cholesterol and phospholipids, and the remainder protein. Peptides can be incorporated into iscoms either directly or by chemical coupling to a carrier protein (e.g. influenza envelope protein) after incorporation of the carrier protein into iscoms.

As an adjuvant, the iscom confers many advantages including powerful immunostimulatory effects, low toxicity, ability to induce both cellular (including CTL) and humoral responses, and it is inexpensive in both reagent and manufacturing cost. However, in the past, iscoms have had two major disadvantages; firstly, the Quil A used in their preparation was a complex and ill-defined mixture of a biologically-derived product, and batch-to-batch variation was therefore to be expected; and secondly, iscoms still showed injection-site reactivity and low but detectable *in vivo* toxicity.

Since the recognition of the adjuvant activity of Quil A (Dalsgaard, 1974) several groups have further fractionated this material into a number of "purified" components (Morein *et al.*, Australian Patent Specification No. 632067; Kersten, 1990; Kensil, 1988; Kensil 1991). These components were subsequently shown to have variable properties especially in regards to adjuvant activity, haemolytic activity and ability to form iscoms. The use of purified Quil A components conferred two potential advantages for their use in a human vaccine. Firstly, the purified component could be characterised and therefore made reproducibly; and secondly, the components could be selected for optimal usefulness.

- 3 -

The immunomodulatory properties of the Quil A saponins and the additional benefits to be derived from these saponins when they are incorporated into an iscom have been described in various publications, e.g. Cox and Coulter, 1992; Dalsgaard, 1974; Morein *et al.*, Australian Patent Specifications Nos. 5 558258, 589915, 590904 and 632067. In Australian Patent Specification No. 632067, the separation of a preparation of Quil A into three distinct fractions called B4B, B3 and B2 is described, along with HPLC chromatographic procedures for this fractionation. More carefully defined and controllable procedures for the fractionation of Quil A have now been devised which result in 10 three major fractions with increasing degrees of hydrophobicity in the purification system used.

In work leading to the present invention, it has now been shown that saponins derived from *Quillaja saponaria* can be separated into fractions with 15 differing chemical and biological properties, including the important biological properties of adjuvant activity, haemolytic activity, ability to form iscoms and *in vivo* toxicity, and that particular compositions of these fractions can be prepared to form novel saponin preparations which are capable of forming good iscoms, having optimal adjuvant activity but minimal haemolytic and toxic activity.

20

SUMMARY OF THE INVENTION

According to the present invention, there is provided a saponin preparation comprising saponins of *Quillaja saponaria*, said preparation comprising from 50 to 90% by weight of Fraction A of Quil A (as herein defined) and from 50% to 25 10% by weight of Fraction C of Quil A (as herein defined).

Preferably, the saponin preparation comprises from 50% to 70% by weight of Fraction A and from 50% to 30% by weight of Fraction C. A particularly preferred preparation comprises about 70% by weight of Fraction A and about 30 30% by weight of Fraction C.

- 4 -

The term "Quil A" is used throughout this specification and in the claims as a generic description of a semi-purified saponin fraction of *Quillaja saponaria*.

5 The saponin preparation may, if desired, include minor amounts (for example up to 40% by weight) of other adjuvant materials with desired immunomodulatory properties, including minor amounts of Fraction B of Quil A or of other saponins. Examples of other saponins or other adjuvant materials which are suitable for inclusion in this preparation are described in Australian Patent Specification No. 632067, incorporated herein by reference.

10

As described above, it is known that in order to prepare an immunostimulating complex (iscm) matrix, Quil A, a sterol such as cholesterol and optionally a lipid such as phosphatidyl choline, must be included in the reaction mixture.

15

In accordance with another aspect of the present invention there is provided an immunostimulating complex (iscm) matrix comprising a saponin preparation, a sterol and optionally a lipid, wherein the saponin preparation comprises from 50 to 90% by weight of Fraction A of Quil A (as herein defined)
20 and from 50% to 10% by weight of Fraction C of Quil A (as herein defined).

Preferably, in such an iscm matrix the sterol is cholesterol, and the lipid (which is optionally present) is a phospholipid such as phosphatidyl choline.

25 In yet another aspect, this invention provides an immunogenic iscm which comprises an iscm matrix as described above having at least one immunogen incorporated into or associated with the iscm matrix.

30 An iscm matrix or an immunogenic iscm in accordance with the present invention may be prepared by techniques which are well known to persons skilled in the art, and which are described in detail in the publications Cox and Coulter, 1992 and Morein *et al.*, Australian Patent Specifications Nos. 558258, 589915,

- 5 -

590904 and 632067, the disclosures of which are incorporated herein by reference.

5 The immunogen which is incorporated into or associated with the iscom matrix in accordance with this invention may be any chemical entity which can induce an immune response in an individual such as (but not limited to) a human or other animal, including but not limited to a humoral and/or cell-mediated immune response to bacteria, viruses or other microorganisms.

10 The specific immunogen can be a protein or peptide, a polysaccharide, a lipopolysaccharide or a lipopeptide; or it can be a combination of any of these. Particularly, the specific immunogen can include a native protein or protein fragment, or a synthetic protein or protein fragment or peptide; it can include glycoprotein, glycopeptide, lipoprotein, lipopeptide, nucleoprotein, nucleopeptide;
15 it can include a peptide-peptide conjugate; it can include a recombinant nucleic acid expression product. Examples of such immunogens include, but are not limited to, those that are capable of eliciting an immune response against viral or bacterial hepatitis, influenza, diphtheria, tetanus, pertussis, measles, mumps, rubella, polio, pneumococcus, herpes, respiratory syncytial virus, haemophilias
20 influenza, chlamydia, varicella-zoster virus, rabies or human immunodeficiency virus.

The present invention also extends to a vaccine composition comprising as the active component thereof either (i) an immunogenic iscom as broadly
25 described above or (ii) an iscom matrix as broadly described above and at least one immunogen, together with one or more pharmaceutically acceptable carriers and/or diluents.

The formulation of such vaccine compositions is well known to persons
30 skilled in this field. Suitable pharmaceutically acceptable carriers and/or diluents include any and all conventional solvents, dispersion media, fillers, solid carriers, aqueous solutions, coatings, antibacterial and antifungal agents, isotonic and

- 6 -

absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art, and it is described, by way of example, in *Remington's Pharmaceutical Sciences*, 18th Edition, Mack Publishing Company, Pennsylvania, USA. Except insofar as any conventional
5 media or agent is incompatible with the active ingredient, use thereof in the pharmaceutical compositions of the present invention is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

It is especially advantageous to formulate compositions in dosage unit form
10 for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the human subjects to be treated; each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier and/or diluent. The specifications for the
15 novel dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active ingredient and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active ingredient for the particular treatment.

20 In yet another aspect, the present invention extends to a method of eliciting or inducing an immune response in an individual, which comprises administering to the individual an immunologically effective amount of a vaccine composition as broadly described above.

25 As previously mentioned, the individual may be a human or other animal, including a livestock animal (eg. sheep, cow or horse), laboratory test animal (eg. mouse, rat, rabbit or guinea pig), companion animal (eg. dog or cat) or wild animal.

30 An immunologically effective amount means that amount necessary at least partly to attain the desired immune response, or to delay the onset of, inhibit the progression of, or halt altogether, the onset or progression of the particular

- 7 -

condition being treated. This amount varies depending upon the health and physical condition of the individual to be treated, the taxonomic group of individual to be treated, the capacity of the individual's immune system to synthesise antibodies, the degree of protection desired, the formulation of the vaccine, the
5 assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials.

Throughout this specification and the claims which follow, unless the
10 context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

15 DETAILED DESCRIPTION OF THE INVENTION

The purification of crude aqueous Quil A extract to Fractions A, B and C of Quil A is described in detail in Example 1 hereinafter. It should be understood that this purification procedure is included by way of example only, and that fractions functionally similar or equivalent to Fractions A, B and C can be
20 prepared by diverse other chromatographic procedures.

For the purposes of identification of Fractions A, B and C referred to herein, reference may be made to the purification procedure of Example 1. In general terms, in this procedure Fractions A, B and C are prepared from the
25 lipophilic fraction obtained on chromatographic separation of the crude aqueous Quil A extract and elution with 70% acetonitrile in water to recover the lipophilic fraction. This lipophilic fraction is then separated by semipreparative HPLC with elution using a gradient of from 25% to 60% acetonitrile in acidic water. The fraction referred to herein as "Fraction A" or "QH-A" is, or corresponds to, the
30 fraction which is eluted at approximately 39% acetonitrile. The fraction referred to herein as "Fraction B" or "QH-B" is, or corresponds to, the fraction which is eluted at approximately 47% acetonitrile. The fraction referred to herein as

- 8 -

"Fraction C" or "QH-C" is, or corresponds to, the fraction which is eluted at approximately 49% acetonitrile.

When prepared as described herein, Fractions A, B and C of Quil A each
 5 represent groups or families of chemically closely-related molecules with definable properties. The chromatographic conditions under which they are obtained are such that the batch-to-batch reproducibility in terms of elution profile and biological activity is highly consistent.

10 Fractions A, B and C as described above have been studied for their adjuvant activity, haemolytic activity and ability to form iscoms, and the results are summarised in Table 1:

TABLE 1 Properties of Fractions A, B and C of Quil A.

Fraction	Adjuvant Activity	Haemolytic activity	Iscom-forming ability
A	medium	very low	very high
B	very high	very high	medium
C	high	high	medium

Surprisingly, it has now been found that particular combinations of Fractions A and C, more particularly combinations of from 50 to 90% by weight of Fraction A with from 50 to 10% by weight of Fraction C (with 0% of Fraction B), result in a saponin preparation which has the desirable properties of A (good
 5 iscom formation and low haemolytic activity) and the benefits of C (good adjuvant activity). In one particularly preferred saponin preparation of this invention, the ratio of 7 parts A: 0 parts B: 3 parts C (=7,0,3; or QH703) has been found to provide very good adjuvant activity, to form iscoms easily yet to have a much lower haemolytic activity than would be expected from the component fractions.

10 It is to be understood, however, that the present invention extends to other saponin preparations ranging from 5 parts A: 0 parts B: 5 parts C (=5,0,5; or QH505) to 9 parts A: 0 parts B: 1 part C (=9,0,1; or QH901).

- 9 -

The following Examples describe a method for the purification of A, B, and C; and compare pure A (10,0,0), pure B (0,10,0), pure C (0,0,10) and the mixture QH703 (7,0,3) in terms of adjuvant activity, haemolytic activity, ease of iscom formation and induction of IL-1, a marker for immunomodulatory activity. Data is also included to demonstrate the pre-clinical safety profile of the saponin preparation of this invention and iscom matrix made therefrom, as well as the clinical safety of this iscom matrix. The overall conclusions from this data is that a mixture of A and C, roughly in the ratio 7:3 (=7,0,3; or QH703) is an optimal ratio of purified saponins from which to form iscom matrix or immunogenic iscoms.

Further features of the present invention are more fully described in the following Example(s). It is to be understood, however, that this detailed description is included solely for the purposes of exemplifying the present invention, and should not be understood in any way as a restriction on the broad description of the invention as set out above.

In the accompanying drawings:

Figure 1 shows the preparation of fractions A, B and C by HPLC;

Figures 2 to 4 show sucrose gradient elution profiles in preparation of iscom matrix; and

Figure 5 shows plasma IL-1 levels in mice following dosing with various quantities and compositions of Quil A and fractions thereof.

- 10 -

EXAMPLE 1**Purification of crude Quil A extract to fractions A, B and C.**

A solution (0.5ml) of crude Quillaja bark extract in water (0.5 g/ml) is
5 pretreated on a sep-pak column (Waters Associates, MA).

The pretreatment involves washing of the loaded sep-pak column with 10%
acetonitrile in acidic water in order to remove hydrophilic substances. Lipophilic
substances including QH-A, QH-B and QH-C are then eluted by 70% acetonitrile
10 in water.

The lipophilic fraction from the sep-pak column is then separated by a
semipreparative HPLC column (CT-sil, C8, 10 X 250mm, ChromTech, Sweden).
The sample is eluted through the column by a gradient from 25% to 60%
15 acetonitrile in acidic water. Three fractions are collected from the HPLC column
during the separation. The residues after evaporation of these three fractions
constitute QH-A, QH-B and QH-C.

The fractions designated QH-A, QH-B and QH-C were eluted at
20 approximately 39, 47 and 49% acetonitrile respectively. The exact elution profile
and conditions are shown in Figure 1.

EXAMPLE 2

**Formation of iscoms with purified QH-A, QH-B and QH-C, either alone or in
25 combination.**

Subunits of iscoms result from the interaction of Quillaja saponins and
cholesterol. Phospholipids are then involved in the assembly of the subunits into
the iscom matrix structure. A typical reaction mixture for the preparation of iscom
30 matrix is 5mg/ml Quil A and 1mg/ml each for cholesterol and phospholipid. The
following experiments were performed to determine the optimal reaction
conditions for various Quil A fractions. The assumption behind these experiments

- 11 -

is that the more stable the interaction between Quil A and cholesterol/phospholipid, the better suited the structure will be to incorporate immunogens without disruption and concomitant increased haemolytic activity.

5 MATERIALS

Cholesterol and ^3H -cholesterol (4211 cpm/ μg)
10 mg/ml (w/v) in 20% MEGA -10 (w/w) in H_2O

10 Phosphatidyl choline and ^3H -phosphatidyl choline
10 mg/ml (w/v) in 20% MEGA-10 (w/w) in H_2O

QH-A and QH-C
100 mg/ml (w/w) in H_2O

15

PBS

Dialysis tubing, MW cut off 12-14.000

20 Method

Reaction mixtures were setup as shown in Tables 2 and 3 and incubated for 2h at room temperature prior to extensive dialysis against PBS at room temperature.

25 All samples were then subjected to Sucrose gradient centrifugation, 10-50% (w/w) sucrose, 200.000 x g (Raver), 10°C, 18h, 11.4ml tubes (Rotor TST 41.14 eq to SW - 40)

The sucrose gradient profiles are shown in Figures 2 to 4 for experiments
30 1 to 3 respectively.

The conclusions from these experiments are summarised below:

- 12 -

Exp 1a - d

The ratio of Cholesterol:QH-A giving a homogenous preparation of matrix is 1c, i.e., the one made with an initial ratio of CHOL:QHA = 1:4 (prior to dialysis), giving a 1:2 ratio in the isolated final product. The mixtures with a higher ratio of

5 CHOL (1a-b) produced opalescent-slightly opalescent preparations in which not all cholesterol is bound by the QH. The preparation with lower CHOL:QHA ratio (1d) did not give rise to a homogenous preparation of matrix, this preparation contained a lot of small fragments (upper peak).

10 Exp 2a - d

The ratio of cholesterol:QH-C giving a homogenous preparation of matrix is 2b, i.e., the one made with an initial ratio of CHOL:QHC = 1:2 (prior to dialysis), giving a 1:1.4 ratio in the isolated final product. The mixture with a higher ratio of CHOL (2a-) produced opalescent preparation in which not all cholesterol is

15 consumed by the QH. The preparation with lower CHOL:QHC ratio (2c-d) did not give rise to homogenous preparations of matrix, preparation 2c contained some small fragments (upper peak) and preparation 2d a considerable amount of fragments.

20 Exp 3a - d

In this experiment the same amounts of QH-A and cholesterol were mixed as in EXP 1a -d but PC was also included in amounts equal to CHOL.QH Double mixtures were prepared with either CHOL or PC labelled (^3H). As shown in the figures 3a-d the ideal ratio of CHOL:QHA is not affected still the initial ratio in the

25 mixture should be 1:4 (3c) but PC helps to keep the complex together in exp 3d compared to 1d.

From the above, two conclusions can be drawn.

30 i) the ratio of lipid and cholesterol to QH is optimal at 1:4 through to 1:5.

- 13 -

- ii) the mixture of QH-A and QH-C which will most accurately balance the ratios of cholesterol to QH so that neither cholesterol nor QH is in excess is QH703. For example, if a 1:5 ratio is used, then chol:QH-A ratio is 1:3.5 and chol:QH-C is 1:1.5, both very close to the optimal ratios determined in experiments 1 and 2.

5

TABLE 2: Incubation ratios for preparing iscom matrix for experiments 1 and 2.

	QH-A	QH-C	3H-CHOL	PBS
1a	0.5 mg (5 μ l)		0.5 mg (50 μ l)	445 μ l
1b	1.0 mg (10 μ l)		0.5 mg (50 μ l)	440 μ l
1c	2.0 mg (20 μ l)		0.5 mg (50 μ l)	430 μ l
1d	3.0 mg (30 μ l)		0.5 mg (50 μ l)	420 μ l
2a		0.5 mg (5 μ l)	0.5 mg (50 μ l)	445 μ l
2b		1.0 mg (10 μ l)	0.5 mg (50 μ l)	440 μ l
2c		2.0 mg (20 μ l)	0.5 mg (50 μ l)	430 μ l
2d		3.0 mg (30 μ l)	0.5 mg (50 μ l)	420 μ l

TABLE 3: Incubation ratios for preparing iscom matrix for experiment 3.

	QH-A	3H-CHOL	CHOL	3H-PC	PC	PBS
3a	0.5mg(5 μ l)	0.5mg(50 μ l)			0.5mg(50 μ l)	395 μ l
3b	0.5mg(5 μ l)		0.5mg(50 μ l)	0.5mg(50 μ l)		395 μ l
3c	1.0mg(10 μ l)	0.5mg(5 μ l)			0.5mg(50 μ l)	390 μ l
3d	1.0mg(10 μ l)		0.5mg(50 μ l)	0.5mg(50 μ l)		390 μ l
3e	2.0mg(20 μ l)	0.5mg(50 μ l)			0.5mg(50 μ l)	385 μ l
3f	2.0mg(20 μ l)		0.5mg(50 μ l)	0.5mg(50 μ l)		385 μ l
3g	3.0mg(30 μ l)	0.5mg(50 μ l)			0.5mg(50 μ l)	380 μ l
3h	3.0mg(30 μ l)		0.5mg(50 μ l)	0.5mg(50 μ l)		380 μ l

EXAMPLE 3

Immunogenicity and efficacy studies on influenza virus iscoms formed from QH-A, QH-B, QH-C and QH703.

5

Aim: To determine the relative efficacy of various combinations of 'Quil A human' (QH) components A, B and C in Iscoms.

Experimental Conditions

10

1. Quil A components A, B and C supplied in powder form.
2. Iscoms were made of QH components A, B and C in the following formulations; (a) 10:0:0, (b) 0:10:0, (c) 0:0:10, or (d) 7:0:3.

15

Preparation of iscom-matrix and protein-iscoms

- 15 -

The following solutions are prepared:

20% w/w mega 10 in distilled water

10mg/ml cholesterol together with 10mg/ml egg PC in 20% mega-10

5 100mg/ml QH703 in pH 6.2 phosphate buffered Saline

Where protein iscoms are being made, the protein to be incorporated should be at about 0.75mg/ml.

10 **Method:**

To 0.8ml of phosphate buffered saline (PBS), pH7.4 (in the case of iscom matrix) or 0.8ml of 0.75mg/ml protein in PBS, pH7.4 (in the case of protein-iscoms).

15 Add 80 μ l of cholesterol/egg PC in mega-10, mix.

Add 40 μ l of 100mg/ml QH703, mix.

Stir overnight at room temperature (22-24°C).

Dialyse against PBS, pH7.4 for 4 hours at room temperature, followed by 4 hours against pH 6.2 PBS.

20 Finally dialyse against pH6.2 PBS at 4°C.

3. Vaccines were prepared using 0.1 μ g or 1.0 μ g influenza virus HA per dose, and 6 μ g or 15 μ g of QH per dose. The strain used was a mouse virulent strain of A/PR/8/34.

25

4. Mice were 6 - 8 weeks of age, 15 per group Balb/C mice were used for all groups.

5. Mice received 0.1 ml dose, subcut. on the back. They were weighed at 0
30 time, and at 3 and 7 days post-primary immunisation.

6. All mice were bled at 4 weeks post-primary immunisation.

- 16 -

7. Mice in groups 1a - 21a (5 mice/group) were boosted at this time (4 weeks) and bled 7 - 10 days later.
8. Groups 1 - 21 were challenged by aerosol challenge at 5 weeks. Groups 1a - 21a were not challenged.
9. Primary and secondary bleeds were assayed for antibody response to whole virus.

The results are shown in Table 4. It can be seen that influenza virus HA incorporated into iscoms made from pure QH-A = 10, 0, 0 (groups 1 to 4) were generally less immunogenic than those made from a mixture of 7 parts QH-A and 3 parts QH-C = 7, 0, 3 (groups 13 - 16). Primary titres for group 4 were significantly lower ($p < .01$) than those for group 16. These iscom preparations were also less protective as shown by less than 100% protection on subsequent challenge. Significant weight loss was also shown by survivors in group 1; the extent of weight loss being a further indicator of the level of protection afforded by vaccination.

10

Similarly, primary titres for groups 14 and 16 were significantly higher than those for groups 10 and 12 respectively. QH703 at 6 $\mu\text{g}/\text{dose}$ was also at least as effective as whole Quil A at 10 $\mu\text{g}/\text{dose}$ (compare groups 13 and 17).

- 15 In summary, these experiments show that the use of QH703 permits at least the same immunogenicity and efficacy as shown by the more toxic fractions of Quil A but with a much lower level of those toxic components.

- 17 -

TABLE 4: Immunogenicity and efficacy results for QH iscoms in mice.**QH ISCOM**

Grp No.	QH Formula	Dose QH (μg)	Dose HA (μg)	Median Titre (Range)		Weight ^c		Survivors ^c %
				1 ^a	2 ^b	Change %		
1	10:0:0	6	0.1	6(0-1049)	57(2-1488)	-15.2		70
2	10:0:0	6	1	19(0-650)	187(68-980)	-1.3		90
3	10:0:0	15	0.1	9(0-597)	58(28-337)	-7.2		100
4	10:0:0	15	1	27(2-209)	536(444-722)	-2.4		100
5	0:10:0	6	0.1	27(0-490)	245(9-523)	-6.7		90
6	0:10:0	6	1	52(8-653)	389(78-2945)	-2.2		100
7	0:10:0	15	0.1	57(0-748)	352(0-971)	-2.4		100
8	0:10:0	15	1	72(15-317)	805(331-1279)	-1.8		100
9	0:0:10	6	0.1	17(0-914)	53(23-104)	-9		100
10	0:0:10	6	1	11(0-183)	131(12-977)	-2.9		100
11	0:0:10	15	0.1	41(6-380)	389(180-2650)	-5.1		100
12	0:0:10	15	1	41(6-380)	1327(342-2052)	-2.3		100
13	7:0:3	6	0.1	40(2-681)	697(121-812)	-2.4	-6	100
14	7:0:3	6	1	62(2-302)	327(163-1714)	0	-0.4	100
15	7:0:3	15	0.1	38(10-759)	563(105-1906)	-3.7	-2.6	100
16	7:0:3	15	1	96(7-424)	870(463-1887)	-2	-0.9	100

- (a) 15 mice/group;
(b) 5 mice/group;
(c) 10 mice challenged/group.

- 18 -

CONTROLS

Grp No.	Vaccine Formulation	Challenge	Dose HA (μ g)	Median Titre (Range)		Weight ^c Change %	Survivors ^c %
				1 ^a	2 ^b		
17	Quil A 10 μ g/dose	PR8	0.1	32(11-67)	226(111-558)	-1.9	100
18	Split virus	PR8	0.1	1(0-23)	3(0-55)	-14.2	57
19	Split virus	PR8	1	2(0-150)	4(0-502)	-14	100
20	Sham (PBS)	PR8	0	0(0-2)	0	-24.5	14
21	Sham (PBS)	PR8	0	0(0-144)	0(0-3)	-26.4	14

- (a) 15 mice/group
(b) 5 mice/group;
(c) 10 mice challenge/group.

EXAMPLE 4

Immunogenicity studies on influenza virus protein iscoms formed from QH703.

5

In this experiment, sheep, 10 per group, were dosed twice by deep intramuscular injection, 4 weeks apart with disrupted virus (B/Panama) virus-iscoms or disrupted virus plus iscom matrix. All iscom vaccines contained 60 μ g/dose QH703. Animals were bled immediately prior to the second dose of vaccine and again one week after the second dose. Sera were assayed by EIA for antibody to virus. The results are shown in the Table 5.

10

TABLE 5: Immunogenicity of QH703 influenza iscoms in sheep

Group	Vaccine	dose, HA μ g	EIA Titre, Median (Range)	
			<u>Primary</u>	<u>Secondary</u>
1	Virus-iscoms	10	43 (12-173)	1694 (420-16803)
2	Virus + iscom-matrix	10	11 (7-28)	2197 (664-3544)
3	Virus	10	2 (2-4)	8 (3-28)

EXAMPLE 5**Immunogenicity of QH703 DT-LHRH iscoms in cats.**

- 5 Cats were dosed twice at 4 week interval with 5mg of a conjugate of diphtheria toxoid to which the decapeptide LHRH was coupled at a peptide to protein molecular ratio of 20:1. One group of 7 cats received conjugate alone, the other group of 7 cats received conjugate mixed with 100 μ g QH703 iscom matrix. Results are presented in Table 6 for the estimation of antibody to the
- 10 LHRH peptide, as measured by EIA. It can be seen that the QH703 iscom matrix has a significant adjuvant effect ($p < .01$), increasing the median titre 6 fold.

- 20 -

TABLE 6: Immunogenicity of QH703 iscom matrix with DT-LHRH conjugate in cats.

ANTI LHRH ANTIBODY TITRE	
Group 1 - conjugate alone	Group 2 - QH703 iscoms plus conjugate
<20	230
<20	287
<20	314
70	427
90	440
115	780
315	793

EXAMPLE 6**IL-1 induction by various mixtures of Quillaja saponins.**

- 5 Preparations of Quil A, QH-C and mixtures of QH-A and QH-C in the ratios 7:3 (= QH703), 5:5(= QH505) and 3:7 (= QH307) were used to make iscom matrices according to standard procedures (see Example 3). These iscoms were dosed into mice subcutaneously at doses ranging from 1 to 20 μ g per mouse. Plasma samples were removed 8 hours later and tested for IL-1 by EIA. The
- 10 results in Figure 5 show that QH703 was significantly different to the other preparations in its ability to induce IL-1 production. It is considered that this response is a useful marker for the potential immunomodulatory activity of iscoms made from these various components and mixtures.

EXAMPLE 7**Haemolytic activity of Quil A and various QH fractions and mixtures.****Assay protocol**

- 5 Human blood (20ml) is collected in a lithium heparin blood collection tube, washed twice in a glucose citrate solution by centrifugation at 3000g, 4°C for 15 minutes then the red cells resuspended in glucose citrate solution.

- Saponin solutions for testing are diluted by doubling dilution from 800
10 µg/ml in a 96-well microtitre tray. To each of these wells is added sufficient of a red blood cell suspension such that, if total haemolysis were to occur, the absorbance at 405 nm in an EIA plate reader would be around 1.0.

- Saponin solution and red cells are mixed gently, incubated for 1 hour at
15 37°C then the plates are centrifuged at 1000g, 4°C for 2 minutes then the absorbance at 405 nm read in an EIA plate reader. Results are expressed as the concentration of saponin preparation required to give 50% haemolysis. The higher the concentration required, the less haemolytic the preparation.

- 20 A number of different samples of QH-A, QH-B, QH-C and QH703 were tested for their haemolytic titre in solution and representative samples were used to prepare influenza iscoms and iscom matrix, which in turn were tested for haemolytic activity. The results are presented in Table 7. It can be seen that, in solution, QH703 has the haemolytic activity that would be expected from a
25 mixture of QH-A and QH-C in those ratios. The order of activity from highest to lowest QH-B > QH-C > QH703 > QH-A.

- However, when these saponins are used to make iscoms, the degree to which the haemolytic activity is decreased is variable ranging from ~ 10 fold for
30 QH-B and QH-C and 40 fold for QH-A and QH703. It is therefore demonstrated that the use of QH703 in iscoms is an optimal way to incorporate adjuvant active quantities of QH-C whilst minimising the haemolytic activity of this saponin.

- 22 -

TABLE 7: Haemolytic activity of various saponins in solution and as iscoms

QH Fraction	Haemolytic activity ($\mu\text{g/ml}$)					
	In solution			Iscom		
	no. tested	median	range	no. tested	median	range
A	6	20	7-40	2	>800	-
B	1	1	-	2	12.5	9-19
C	6	3	1-5	2	20	-
703	7	4	2-10	16	150	75-600

EXAMPLE 8**Pre-clinical safety of QH703.**

- QH703 as well as iscom matrix and immunogenic iscoms prepared from
- 5 QH703 were subjected to pre-clinical toxicological and safety testing to prove their safety prior to the commencement of clinical studies in humans. Iscom matrix and influenza iscoms were prepared by the method of Example 3.

The following mutagenicity tests were conducted using QH703:

10

Ames test

Chromosomal aberration study using cultured mammalian cells

Micronucleus test in bone marrow of CD-1 mice

Mouse lymphoma mutation assay.

15

The following toxicological studies were conducted:

- 23 -

Single dose:

QH703 intramuscularly in rats

Iscom matrix prepared from QH703 intramuscularly in rats

Pyrogenicity of influenza iscoms prepared from QH703 in rabbits.

5

Repeat dose studies:

QH703 intramuscularly in rats, daily for 14 days

Iscom matrix prepared from QH703 intramuscularly in rats, daily for 14 days

10 Iscom matrix prepared from QH703, local tolerance in rabbits, 6 doses at 2 weekly intervals

Influenza iscoms prepared from QH703, local tolerance in rabbits, 6 doses at 2 weekly intervals.

15 The conclusions from the mutagenicity studies with QH703 were that QH703 was not considered to produce mutagenic effects in the test systems used and was unlikely to produce any mutagenic effects in man.

The conclusions from the single dose toxicological studies were that it was
20 difficult to clearly establish the "No Toxic Effect Level" in these studies, with QH703 and iscom matrix prepared from QH703 showing limited non-specific lethality in high doses (10 mg.kg^{-1} and 1.4 mg.kg^{-1} respectively). These doses represent greater than 1000 times the dose which is believed to be the maximum therapeutic dose.

25

The safety of QH703 and iscom matrix prepared from QH703 was confirmed in the other studies in rats and rabbits. At high doses, the effects which were observed could in part be contributed to the immunological (adjuvant) activity of the test material.

30

- 24 -

Influenza Iscom Vaccine was shown to be well tolerated in the rabbit local tolerance study for the full 6 doses, at doses of 100 μ g of iscom matrix (measured as QH703) per dose.

- 5 Pyrogenicity testing with a single 100 μ g dose of Influenza Iscom Vaccine (measured as QH703) into rabbits has shown the vaccine to be non-pyrogenic.

EXAMPLE 9

Clinical safety of iscom matrix prepared from QH703 in humans.

10

Healthy male and female volunteers aged between 18 and 45 years of age who satisfied the inclusion/exclusion criteria for the study were each injected intramuscularly with 0.5 ml containing one of the following preparations in a single blind placebo controlled trial;

15

- (i) placebo (diluent)
- (ii) 25 μ g of iscom matrix prepared from QH703
- (iii) 50 μ g of iscom matrix prepared from QH703
- (iv) 100 μ g of iscom matrix prepared from QH703
- 20 (v) 200 μ g of iscom matrix prepared from QH703.

Iscom matrix was prepared from QH703 by the method of Example 3. The conclusions from the study were that all four dose levels of iscom matrix prepared from QH703 were well tolerated in healthy male and female volunteers.

25

Persons skilled in this art will appreciate that variations and modifications may be made to the invention as broadly described herein, other than those specifically described without departing from the spirit and scope of the invention.

30 It is to be understood that this invention extends to include all such variations and modifications.

REFERENCES:

Cox, J.C. and Coulter, A.R. (1992), "Advances in Adjuvant Technology and Application", *in* Animal Parasite Control Utilizing Biotechnology, Chapter 4, Ed. Yong, W.K. CRC Press.

Dalsgaard, K. (1974), *Arch. Gesamte Virusforsch*, **44**, 243.

Kensil, C.A., *et al.* (1988), International Patent Application No. PCT/US88/01842.

Kensil, C.A. *et al.* (1991), *J. Immunol.*, **146**, 431.

Kersten, G.F.A. *et al.* (1990). "Aspects of Iscoms. Analytical, Pharmaceutical and Adjuvant Properties; Thesis, University of Utrecht.

- 26 -


CLAIMS:

1. A saponin preparation comprising saponins of *Quillaja saponaria*, said preparation comprising from 50% to 90% by weight of Fraction A of Quil A (as herein defined) and from 50% to 10% by weight of Fraction C of Quil A (as herein defined).
2. A saponin preparation according to claim 1, comprising from 50% to 70% by weight of Fraction A and from 50% to 30% by weight of Fraction C.
3. A saponin preparation according to claim 1, comprising about 70% by weight of Fraction A and about 30% by weight of Fraction C.
4. An immunostimulatory complex (iscom) matrix, comprising a saponin preparation according to any of claims 1 to 3, a sterol and optionally a lipid.
5. An iscom matrix according to claim 4, wherein the sterol is cholesterol.
6. An iscom matrix according to claim 4, wherein the lipid, when present, is a phospholipid such as phosphatidyl choline.
7. An immunogenic iscom which comprises an iscom matrix according to any of claims 4 to 6, having at least one immunogen incorporated into or associated with said iscom matrix.
8. A vaccine composition which comprises, as the active component thereof, either (i) an iscom matrix according to any of claims 4 to 6, and at least one immunogen, or (ii) an immunogenic iscom according to claim 7, together with one or more pharmaceutically acceptable carriers and/or diluents.



- 27 -

9. A method of eliciting or inducing an immune response in an individual, which comprises administering to said individual an immunologically effective amount of a vaccine composition according to claim 8.



1/8

FIG 1


2/8

FIG 2(1a)FIG 2(1b)



3/8

FIG 2(1c)FIG 2(1d)

4/8

FIG 3(2a)FIG 3(2b)

5/8

FIG 3(2c)FIG 3(2d)

6/8

FIG 4(3a/3b)







FIG 4(3c/3d)



7/8

FIG 4(3e/3f)FIG 4(3g/3h)

8/8




FIG 5

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/AU 95/00670

A. CLASSIFICATION OF SUBJECT MATTER

Int Cl⁶: A61K 47/46, 47/28, 47/26, C07G 3/00, C07J 63/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC A61K C07G C07J

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

AU: IPC A61K 47/46, 47/28, 47/26, 47/00, 9/127, 9/133, C07G 3/00, C07J 63/00

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

DERWENT: QUILLAJA(SAPONARIA: OR QUIL(A or SAPONIN:

CHEMICAL ABSTRACTS: QUILLAJA(SAPONARIA: or QUIL(A

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 92/06710 A (DE STAATDER NEDERLANDEN VERTEGENWOORDIGDDOOR DE MINISTER VAN WELZIJN VOLKSGEZONDHEID EN CULTUUR) 30 April 1992 entire document	1-9
A	WO 88/09336 (CAMBRIDGE BIOSCIENCE CORPORATION) 1 December 1988 entire document	1-9
A	WO 93/05789 (CAMBRIDGE BIOSCIENCE CORPORATION) 1 April 1993 entire document	1-9



Further documents are listed in the continuation of Box C



See patent family annex

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search
4 January 1995

Date of mailing of the international search report
16.01.1996

Name and mailing address of the ISA/AU
AUSTRALIAN INDUSTRIAL PROPERTY ORGANISATION
PO BOX 200
WODEN ACT 2606
AUSTRALIA Facsimile No.: (06) 285 3929

Authorized officer

T. SUMMERS

Telephone No.: (06) 283 2291

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/AU 95/00670

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94/01118 (CAMBRIDGE BIOSCIENCE CORPORATION) 20 January 1994 entire document	1-9
A	WO 90/03184 (MOREIN, Bror et al.) 5 April 1990 examples 6 and 7	1-9
A	WO 95/09179 (SEED CAPITAL INVESTMENT B.V.) 6 April 1995 entire document	1-9
A	COX, J.C. and COULTER, A.R. (1992) "Advances in Adjuvant Technology and Application" in <u>Animal Parasite Control Utilizing Biotechnology</u> , Chapter 4, Ed. Yong, W.K. CRC Press, pages 59-62	1-9
A	KENSIL, C.R. et al., "Separation and characterization of saponins with adjuvant activity from <i>Quillaja saponaria molina cortex</i> ", 15 January 1991, <i>J. Immunology</i> , 146, (2), 431-437. entire document	1-9

INTERNATIONAL SEARCH REPORT
Information on patent family members

International Application No.
PCT/AU 95/00670

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
WO	9206710	EP	555276	NL	9002314		
WO	8809336	AU	19340/88	CA	1331443	DK	6029/89
		EP	362279	US	5057540		
WO	9305789	AU	26664/92	EP	606317	NO	940949
		NZ	244410				
WO	9401118	AU	46649/93	EP	658111	FI	946173
		NO	945071	US	5273965		
WO	9003184	AU	43374/89	DK	558/91	EP	436620
		HU	56722	NO	911049	NZ	230747
		PT	91856	ZA	8907217		
WO	9509179	NL	9301690	AU	10777/95		
<div>END OF ANNEX</div>							